Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573598 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,219
- Enrollment target
NCT01573598: Completed Phase 4 study, sponsored by Forest Laboratories.
NCT01573598 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 1,219 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01573598, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,219 participants
- Enrollment target
Study Summary
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Interventions
- DRUG Placebo
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,219 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
What the finished NCT01573598 record still lists
NCT01573598 is an interventional study that assigns participants to a tested intervention. Its 1,219 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (135% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01573598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01573598 about?
NCT01573598 is a clinical study titled "Safety and Efficacy of Vilazodone in Major Depressive Disorder". Safety and Efficacy of Vilazodone in Major Depressive Disorder
What is the current status of trial NCT01573598?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,219 participants. The study started on 2012-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01573598?
The interventions under investigation include: Placebo (DRUG), Vilazodone (DRUG).
Who is sponsoring clinical trial NCT01573598?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01573598's enrollment target sits among peer trials
1,219 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia